DE MERCANTI, STEFANIA FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 3.705
EU - Europa 2.036
AS - Asia 765
AF - Africa 71
OC - Oceania 29
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 11
Totale 6.645
Nazione #
US - Stati Uniti d'America 3.658
IT - Italia 509
CN - Cina 440
IE - Irlanda 269
SE - Svezia 262
FR - Francia 185
DE - Germania 144
FI - Finlandia 103
UA - Ucraina 103
GB - Regno Unito 97
VN - Vietnam 90
DK - Danimarca 83
AT - Austria 70
BE - Belgio 58
KR - Corea 58
SN - Senegal 48
CA - Canada 41
JP - Giappone 38
ES - Italia 35
IN - India 32
TR - Turchia 24
PL - Polonia 22
AU - Australia 20
IL - Israele 20
NL - Olanda 20
GR - Grecia 19
IR - Iran 18
BR - Brasile 15
SG - Singapore 14
EU - Europa 11
MU - Mauritius 11
RO - Romania 10
NZ - Nuova Zelanda 9
CZ - Repubblica Ceca 8
RU - Federazione Russa 8
HK - Hong Kong 7
PT - Portogallo 7
CO - Colombia 6
NG - Nigeria 6
UZ - Uzbekistan 6
MX - Messico 5
BG - Bulgaria 4
NO - Norvegia 4
TW - Taiwan 4
ZA - Sudafrica 4
CH - Svizzera 3
ID - Indonesia 3
LB - Libano 3
MK - Macedonia 3
BY - Bielorussia 2
CL - Cile 2
EC - Ecuador 2
LV - Lettonia 2
PH - Filippine 2
PK - Pakistan 2
RS - Serbia 2
UY - Uruguay 2
AR - Argentina 1
BD - Bangladesh 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
MD - Moldavia 1
MY - Malesia 1
NP - Nepal 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 6.645
Città #
Chandler 621
Ann Arbor 354
Dublin 265
Beijing 253
Fremont 222
Ashburn 179
Fairfield 159
Torino 151
Houston 129
Nyköping 125
Wilmington 116
Villeurbanne 106
Jacksonville 100
Dearborn 94
Woodbridge 84
Medford 82
Cambridge 77
Princeton 76
Dong Ket 70
Vienna 69
Redwood City 64
Seattle 63
Brussels 50
Milan 43
Turin 41
Boardman 36
New York 30
Boston 28
Pisa 25
Washington 22
Toronto 18
Warsaw 18
San Diego 15
Guangzhou 13
Nanjing 13
Chengdu 12
Rome 12
Dallas 11
Hangzhou 11
Limoges 11
Norwalk 11
Shanghai 11
Tokyo 10
Duncan 9
London 9
Kunming 8
Mountain View 8
San Mateo 8
Zhengzhou 8
Helsinki 7
Istanbul 7
Jinan 7
Madrid 7
Menlo Park 7
Moncalieri 7
Abuja 6
Coventry 6
Dresden 6
Hebei 6
Hefei 6
Los Angeles 6
Ottawa 6
Paris 6
Wuhan 6
Alessandria 5
Beinasco 5
Düsseldorf 5
Heidelberg 5
Kozani 5
Nürnberg 5
Venteuil 5
Fuzhou 4
Istrana 4
Jerusalem 4
Lagarto 4
Mifflinburg 4
Munich 4
Netanya 4
Oldenburg 4
Oulu 4
Phoenix 4
Portland 4
Richmond Hill 4
Rivalta di Torino 4
Settimo Torinese 4
Volos 4
Amsterdam 3
Auckland 3
Barcelona 3
Brecon 3
Bucharest 3
Cankaya 3
Central District 3
Changsha 3
Chicago 3
Cork 3
Curitiba 3
Florence 3
Gazi 3
Hamilton 3
Totale 4.183
Nome #
Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study 568
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 373
Heterozygous deletion of KLHL1/ATX8OS at the SCA8 locus is unlikely associated with cerebellar impairment in humans 346
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 285
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 178
Heterozygous deletion of KLHL1/ATXN8OS at the SCA8 locus are likely not associated with cerebellar impairment in humans 173
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 165
D-dimer Increasing After First Alemtuzumab Administration in a Multiple Sclerosis Patient 150
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 141
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 141
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 134
Natalizumab in Multiple Sclerosis: Long-Term Management 128
The Adaptive Immune System in Multiple Sclerosis: An Estrogen-Mediated Point of View 127
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 123
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 111
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 108
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 102
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 101
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 100
Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question 99
ALS patients and caregivers communication preferences and information seeking behaviour 98
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 87
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 85
Epigenetic therapy for Friedreich ataxia. 82
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 81
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 81
Early weight loss in amyotrophic lateral sclerosis: Outcome relevance and clinical correlates in a population-based cohort 80
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 79
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 79
Prognostic influence of pre-morbid smoking habits, diabetes, arterial hypertension and vascular risk profile on phenotype and outcome of ALS patients: a population-based study. 78
Botulinum toxin for Pisa syndrome: An MRI-, ultrasound- and electromyography-guided pilot study 78
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 75
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 75
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 73
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 72
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 72
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 71
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 70
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 68
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 68
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 67
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 67
Atypical presentation of superficial sclerosis successfully treated with iron chelation 66
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 66
Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia 66
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 64
The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis 64
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 63
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-  62
Ultrasound-guided botulinum toxin-A for sialorrhea: a 2-year prospective study 62
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 61
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 58
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 58
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 57
Digital therapeutics in neurology 56
A real-world study of Alemtuzumab in a cohort of Italian patients 53
Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up 53
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial 52
Management of multiple sclerosis patients after the 24th Natalizumab course: the Ty-STOP study 48
Family functioning and multiple sclerosis: Study protocol of a multicentric italian project 48
Friedreich's ataxia patients and caregivers information seeking behaviour 47
Neutralizing antibodies in multiple sclerosis patients treated with 375 μg interferon-β-1b 46
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series 43
Extended interval dosing of natalizumab: is efficacy preserved? 42
Gut microbiota and metagenomic diversity in Clinical Isolated Syndrome 42
Spinal Cord Compression due to extramedullary hematopoiesis in a young patient affected by beta thalassemia 40
Six year prospective immunological study of alemtuzumab treated patients: identification of markers of the clinical response 40
Role of Th22 expansion in multiple sclerosis disease activity 39
Natalizumab discontinuation after the 24th course: which is the way? The TY-STOP study 35
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 34
PRO-INFLAMMATORY CYTOKINE AND CHEMOKINE MRNA BLOOD LEVEL IN MULTIPLE SCLEROSIS IS RELATED TO TREATMENT RESPONSE AND INTERFERON-BETA DOSE 33
Improving the care of Rebif® treated Multiple Sclerosis patients: the "MSdialog" experience 31
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 25
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 22
Source of medical information and behavioral seeking patterns in patients affected with Friedreich’s ataxia and their caregivers: a survey study 10
Totale 6.925
Categoria #
all - tutte 16.530
article - articoli 0
book - libri 0
conference - conferenze 8.755
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.285


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019169 0 0 0 0 0 0 0 0 17 51 54 47
2019/2020850 23 28 43 118 55 123 91 69 73 99 59 69
2020/20211.017 78 70 55 120 86 79 70 51 114 61 90 143
2021/20221.152 50 42 36 74 48 89 89 65 73 120 261 205
2022/20231.673 137 164 51 196 146 377 119 111 170 66 84 52
2023/2024572 108 107 57 54 61 121 25 39 0 0 0 0
Totale 6.925